53 reports

MARKET ##.

  • Cholesterol
  • APAC
  • Japan
  • United States
  • World

Cholesterol Test Volume and Diagnostics Sales Forecasts by Market Segment Germany: LDL Cholesterol Test Volume and Diagnostics Sales Forecasts by Market Segment Italy: LDL Cholesterol Test Volume and Diagnostics Sales Forecasts by Market Segment Japan: LDL

  • Cholesterol
  • Hospital
  • Japan
  • United States
  • Forecast

Cholesterol Test Volume and Diagnostics Sales Forecasts by Market Segment Germany: LDL Cholesterol Test Volume and Diagnostics Sales Forecasts by Market Segment Italy: LDL Cholesterol Test Volume and Diagnostics Sales Forecasts by Market Segment Japan: LDL

  • Cholesterol
  • Hospital
  • Japan
  • United States
  • Forecast

Cholesterol Test Volume and Diagnostics Sales Forecasts by Market Segment Germany: Cholesterol Test Volume and Diagnostics Sales Forecasts by Market Segment Italy: Cholesterol Test Volume and Diagnostics Sales Forecasts by Market Segment Japan: Cholesterol Test Vo

  • Cholesterol
  • Chronic Disease
  • Diagnostics
  • Forecast

Cholesterol Direct Test Volume and Diagnostics Sales Forecasts by Market Segment Germany: LDL Cholesterol Direct Test Volume and Diagnostics Sales Forecasts by Market Segment Italy: LDL Cholesterol Direct Test Volume and Diagnostics Sales Forecasts by Market Segment Japan:

  • Cholesterol
  • Hospital
  • Japan
  • United States
  • Forecast

Cholesterol Direct Test Volume and Diagnostics Sales Forecasts by Market Segment Germany: LDL Cholesterol Direct Test Volume and Diagnostics Sales Forecasts by Market Segment Italy: LDL Cholesterol Direct Test Volume and Diagnostics Sales Forecasts by Market Segment Japan:

  • Cholesterol
  • Hospital
  • Japan
  • United States
  • Forecast

Cholesterol Test Volume and Sales Forecasts 2021: US, Europe, Japan--Hospitals, Commercial Labs, POC Locations List of Tables France: Cholesterol Test Volume and Diagnostics Sales Forecasts by Market Segment Germany: Cholesterol Test Volume and Diagnostics Sales Forecasts

  • Cholesterol
  • Chronic Disease
  • Japan
  • United States
  • Forecast
  • CHOLESTEROL ABSORPTION INHIBITORS
  • GLOBAL CHOLESTEROL ABSORPTION INHIBITORS MARKET 2016-2021 ($ MILLIONS)

As cholesterol disorder is one of the major causes for CVDs, patients try to strictly adhere to cholesterol maintaining drugs to avoid the occurrence of CVD.

  • Cardiovascular Disease
  • Cholesterol
  • Lipid Modifying Drug
  • Statins
  • AstraZeneca PLC
  • Growing demand from emerging markets
  • Identifying factors impacting market growth

High blood cholesterol levels are highly prevalent and one of the leading causes of cardiovascular diseases among consumers worldwide.

  • Cholesterol
  • World
  • Forecast
  • Archer Daniels Midland Company
  • Cargill Inc.
  • POC Cholesterol Testing
  • POC Cholesterol Self-Testing

Figure ##-## Percent of U. S.

  • Cholesterol
  • Point Of Care Testing
  • Abaxis, Inc.
  • Alere Inc.
  • PTS DIAGNOSTICS
  • PRESENTS THE CHOLESTEROL SYNTHESIS PATHWAY, HIGHLIGHTING THE MECHANISM OF ACTION OF STATINS.
  • DYSLIPIDEMIA: FREDRICKSON CLASSIFICATION SYSTEM

PLOS ONE; ##(##): ##-##.

  • Cholesterol
  • AstraZeneca PLC
  • Cerenis
  • Merck & Co., Inc.
  • The Medicines Company

Cholesterol Test Volume and Diagnostics Sales Forecasts by Market Segment Germany: Cholesterol Test Volume and Diagnostics Sales Forecasts by Market Segment Italy: Cholesterol Test Volume and Diagnostics Sales Forecasts by Market Segment Japan: Cholesterol Test Vo

  • Cholesterol
  • France
  • Germany
  • Italy
  • Forecast

Global Cholesterol Testing Industry CHOLESTEROL TESTING MCP-## MARKET ANALYSIS, TRENDS, AND FORECASTS, MAY ## CONTENTS ##.

  • Cholesterol
  • APAC
  • United States
  • World
  • Company Financials
  • Risk Factors and Comorbidities for Dyslipidemia
  • Executive Summary

Plos One; ##(##): ##-##.

  • Cholesterol
  • China
  • Germany
  • United States
  • Forecast

Evinacumab

8770 10000 7800

These enzymes are involved in the degradation of lipoproteins including low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) particles.

  • Biopharmaceutical
  • Cholesterol
  • Medical Biotechnology
  • Therapy
  • United States

Lipitor

8770 10000 7800

This hepatic pathway is responsible for synthesizing various molecules, including cholesterol.

  • Cholesterol
  • European Union
  • Japan
  • United States
  • Market Description

Crestor

8770 10000 7800

This hepatic pathway is responsible for synthesizing various molecules, including cholesterol.

  • Cholesterol
  • Chronic Disease
  • Pathology
  • United States
  • Forecast

Esperion Therapeutics anticipates filing for the initial approval of bempedoic acid for a lowering of low-density lipoprotein cholesterol in high-risk dyslipidemia patients indication in the first quarter of 2019.

  • Cholesterol
  • European Union
  • Japan
  • United States
  • Supply

Volanesorsen

8770 10000 7800

By inhibiting ApoC-III, volanesorsen reduces circulating levels of TGs, VLDLs, and ApoC-III, and increases HDL cholesterol levels, resulting in a potentially less atherogenic lipid profile in patients who receive the drug.

  • Cholesterol
  • European Union
  • Japan
  • United States
  • Supply

Repatha

8770 10000 7800

This consequently inhibits LDLR degradation, allowing the LDLRs to be recycled to the cell surface, thereby increasing plasma clearance of low-density lipoprotein cholesterol.

  • Cholesterol
  • European Union
  • Japan
  • United States
  • Supply

Kynamro

8770 10000 7800

Therefore, by reducing ApoB-## concentrations, Kynamro also reduces plasma LDL cholesterol concentrations.

  • Cholesterol
  • Lipid Modifying Drug
  • European Union
  • Japan
  • United States
  • CHOLESTEROL TESTING SERVICES MARKET
  • CHOLESTEROL TESTING/CHOLESTEROL SCREENING SERVICES MARKET, BY TYPE OF CUSTOMER

LabCorp is one of the leading players in the cholesterol testing services market.

  • Cholesterol
  • North America
  • United States
  • Market Size
  • OPKO Health, Inc.

Zetia Franchise

8770 10000 7800

Zetia’s position is further threatened by the market entry of the proprotein convertase subtilisin/ kexin type ## inhibitors, which have shown superior low-density lipoprotein cholesterol-lowering abilities in Phase III clinical trials.

  • Cholesterol
  • European Union
  • Japan
  • United States
  • Demand

Other lipid level deviations in dyslipidemia include low levels of HDL-C, elevated total cholesterol, and elevated triglycerides.

  • Cardiovascular Disease
  • Cholesterol
  • Chronic Disease
  • Pathology
  • NOV 13, 2014: GALMED PHARMACEUTICALS ANNOUNCES FIRST ADMINISTRATION OF ARAMCHOL IN ITS PHASE IIA TRIAL FOR THE TREATMENT OF CHOLESTEROL GALLSTONES
  • Aramchol - Drug Profile

ATP Binding Cassette Sub Family A Member ## (ATP Binding Cassette Transporter ## or ABC ## or ATP Binding Cassette ## or Cholesterol Efflux Regulatory Protein or ABCA##) Overview ATP-binding cassette transporter (ABCA##, cholesterol efflux regulatory p

  • Cholesterol
  • United States
  • Company
  • Product Initiative
  • Galmed Pharmaceuticals Ltd.

The others segment encompasses market analysis of combination drug therapies such as Advicor, Vytorin, and Caduet, as well as cholesterol inhibitor drugs.

  • Cholesterol
  • Therapy
  • United States
  • Company Financials
  • Market Size
  • Jun 04, 2014: Recently Published Independent Research Supports the Importance of Reverse Cholesterol Transport on NASH Pathogenesis
  • Nov 13, 2014: Galmed Pharmaceuticals Announces First Administration of Aramchol in its Phase IIa Trial for the Treatment of Cholesterol Gallstones

ATP Binding Cassette Sub Family A Member ## (ATP Binding Cassette Transporter ## or ABC ## or ATP Binding Cassette ## or Cholesterol Efflux Regulatory Protein or ABCA##) Overview ATP-binding cassette transporter (ABCA##, cholesterol efflux regulatory p

  • Cholesterol
  • United States
  • Company
  • Product Initiative
  • Galmed Pharmaceuticals Ltd.
  • There was a significant increase in cholesterol efflux in dalcetrapib-treated AA population, but not the GG genotype
  • JUL 18, 2016: DALCOR DALCETRAPIB DEMONSTRATES GENOTYPE-DEPENDENT EFFECTS ON CHOLESTEROL EFFLUX AND INFLAMMATION IN DATA PUBLISHED BY THE MONTREAL HEART INSTITUTE IN CIRCULATION: CARDIOVASCULAR GENETICS

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Cardiology
  • Cardiovascular Disease
  • Cholesterol
  • Hospital
  • Pfizer Inc.
  • There was a significant increase in cholesterol efflux in dalcetrapib-treated AA population, but not the GG genotype
  • JUL 18, 2016: DALCOR DALCETRAPIB DEMONSTRATES GENOTYPE-DEPENDENT EFFECTS ON CHOLESTEROL EFFLUX AND INFLAMMATION IN DATA PUBLISHED BY THE MONTREAL HEART INSTITUTE IN CIRCULATION: CARDIOVASCULAR GENETICS

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Cardiology
  • Cardiovascular Disease
  • Cholesterol
  • Therapy
  • Pfizer Inc.
  • CHOLESTEROL POP TEST - PRODUCT STATUS
  • CHOLESTEROL POP TEST - PRODUCT DESCRIPTION

Akers Bio' s Tri-Cholesterol " Check" test is the only combined rapid test which provides an estimate of a person' s Total cholesterol as well as their High Density Lipoprotein (" HDL" ) cholesterol levels - their ' good cholesterolx

  • Cholesterol
  • Clinical Trial
  • Infectious Disease
  • Point Of Care Testing
  • Grifols, S.A.